Chimerix Inc
$ 8.54
0.00%
11 Jun - close price
- Market Cap 801,084,000 USD
- Current Price $ 8.54
- High / Low $ 8.54 / 8.54
- Stock P/E N/A
- Book Value 1.32
- EPS -0.99
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.34 %
- ROE -0.56 %
- 52 Week High 0.00
- 52 Week Low 0.00
About
Chimerix, Inc., a developing-stage biopharmaceutical company, focuses on accelerating the advancement of various drugs that impact the lives of patients living with cancer and other serious diseases. The company is headquartered in Durham, North Carolina.
Analyst Target Price
$8.53
Quarterly Earnings
| Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-03-21 | 2024-11-07 | 2024-08-13 | 2024-05-01 | 2024-02-29 | 2023-11-02 | 2023-08-03 | 2023-05-04 | 2023-03-02 | 2022-11-03 | 2022-08-08 | 2022-05-16 |
| Reported EPS | -0.25 | -0.26 | -0.23 | -0.25 | -0.2 | -0.27 | -0.21 | -0.24 | -0.24 | 2.75 | -0.27 | -0.28 |
| Estimated EPS | -0.275 | -0.24 | -0.23 | -0.22 | -0.24 | -0.23 | -0.24 | -0.25 | -0.24 | 2.14 | -0.24 | -0.33 |
| Surprise | 0.025 | -0.02 | 0 | -0.03 | 0.04 | -0.04 | 0.03 | 0.01 | 0 | 0.61 | -0.03 | 0.05 |
| Surprise Percentage | 9.0909% | -8.3333% | 0% | -13.6364% | 16.6667% | -17.3913% | 12.5% | 4% | 0% | 28.5047% | -12.5% | 15.1515% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: CMRX
2026-05-27 04:40:55
The Glioblastoma Multiforme (GBM) market is predicted to grow significantly, from approximately USD 900 million in 2025 to nearly USD 4.8 billion by 2036, driven by an increasing prevalence of the disease and advancements in therapeutic pipelines. Key companies like AstraZeneca, Bayer, and Chimerix are developing new treatments, including vaccine approaches and combination therapies, to address this aggressive brain tumor. The United States is expected to remain the largest market, contributing significantly to the overall revenue.
2026-05-13 01:09:40
The NASDAQ page for Chimerix Inc. (CMRX) provides current stock price information, showing it is trading at $8.54 with no change. The article notes that there are no analyst ratings or earnings information currently available for the company. It also promotes joining an options trading webinar and signing up for free trade alerts.
2026-04-20 16:08:55
The SEC has announced a settled order against Weizheng Zeng for insider trading related to Jazz Pharmaceuticals' acquisition of Chimerix. Zeng, who was involved in the due diligence for the transaction at Jazz, purchased Chimerix stock based on material nonpublic information, resulting in over $69,000 in profits. He has agreed to disgorge his profits, pay prejudgment interest, and a civil penalty without admitting or denying the SEC's findings.
2026-04-02 17:09:44
This article provides an overview of Chimerix, Inc. (CMRX) stock, detailing its current price, market capitalization, and key financial metrics like P/E ratio and EPS. It highlights an AI-powered analysis with a "B" score, indicating moderate investment characteristics, and provides a 12-month price target of $7.96. The analysis also covers the stock's performance changes over various periods and technical indicators such as RSI.
2026-03-12 20:52:38
Chimerix Inc. (CMRX) is trading at $8.54 intraday on NASDAQ, presenting a potential oversold bounce opportunity with key support levels at the 50-day average of $6.67 and the 200-day average of $2.75. Meyka AI rates CMRX with a score of 67 (Grade B, HOLD suggestion), projecting a 1-year price of $7.96, a 3-year price of $12.87, and a 5-year price of $17.76. The article suggests a trade plan focusing on risk control, scaling in near the 50-day average, and using partial profit targets.
2026-02-21 06:54:01
The Smallpox Treatment Market report by DataM Intelligence analyzes trends, developments, and opportunities in the market, forecasting significant CAGR growth between 2024 and 2031. It highlights key players like SIGA Technologies Inc. and Bavarian Nordic A/S, segmenting the market by treatment type (antiviral, vaccines), administration route, and distribution channels. The report also provides a regional analysis and outlines its research methodology and comprehensive coverage.
